Skip to main
ANVS
ANVS logo

Annovis Bio (ANVS) Stock Forecast & Price Target

Annovis Bio (ANVS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Annovis Bio Inc is positioned favorably in the pharmaceutical market, particularly with its lead product, Buntanetap, which has the potential to positively modify disease progression in chronic neurodegeneration, including Alzheimer's and Parkinson's diseases. The company has reported promising interim results from its intrathecal RNAi therapy targeting amyloid precursor protein (APP), indicating a reduction in sAPP and a plan to advance to Phase 2 trials by the second half of 2025. Additionally, Annovis has noted alignment with the FDA regarding the potential filing of a new drug application based on well-executed six-month trial data, enhancing the prospects for future growth and market expansion.

Bears say

Annovis Bio Inc faces significant financing risks due to a modest cash runway, which may necessitate dilutive capital raising activities. The company's focus on creating treatments for challenging neurodegenerative diseases like Alzheimer's and Parkinson's poses additional risks, including potential trial failures related to efficacy and safety, as well as the possibility of regulatory setbacks regarding FDA approvals. Furthermore, even if the products reach the market, there is the threat of underperformance due to increased competition and pricing pressure, which could adversely impact commercial success.

Annovis Bio (ANVS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annovis Bio (ANVS) Forecast

Analysts have given Annovis Bio (ANVS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Annovis Bio (ANVS) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annovis Bio (ANVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.